ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,181.35% | 1,181.12% | 111.32% | -48.46% | 159.17% |
| Total Other Revenue | 111.83% | 182.93% | 578.05% | -- | -- |
| Total Revenue | 2,270.58% | 1,218.71% | 120.95% | -48.46% | 159.17% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2,270.58% | 1,218.71% | 120.95% | -48.46% | 159.17% |
| SG&A Expenses | 28.07% | 27.35% | 37.62% | 44.50% | 26.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.84% | 1.36% | -3.20% | -5.88% | 3.16% |
| Operating Income | 4.75% | 0.51% | 3.40% | 5.81% | -3.05% |
| Income Before Tax | 29.16% | -28.16% | -26.05% | -39.59% | -39.93% |
| Income Tax Expenses | -- | -217.65% | -217.65% | -217.65% | -217.65% |
| Earnings from Continuing Operations | 29.15% | -28.14% | -26.04% | -39.57% | -39.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -87.65% | -88.46% | -86.45% | -46.77% | -12.88% |
| Net Income | 29.09% | -28.33% | -26.25% | -39.73% | -40.00% |
| EBIT | 4.75% | 0.51% | 3.40% | 5.81% | -3.05% |
| EBITDA | 4.73% | 0.19% | 3.30% | 6.00% | -3.14% |
| EPS Basic | 46.85% | 17.17% | 17.36% | -0.02% | -8.23% |
| Normalized Basic EPS | 46.70% | 15.83% | 16.13% | -2.07% | -10.44% |
| EPS Diluted | 43.89% | 15.05% | 17.19% | -0.64% | -8.70% |
| Normalized Diluted EPS | 46.74% | 15.86% | 16.13% | -2.07% | -10.44% |
| Average Basic Shares Outstanding | 37.13% | 54.15% | 51.40% | 39.76% | 27.14% |
| Average Diluted Shares Outstanding | 37.30% | 54.27% | 51.40% | 39.76% | 27.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |